Ainos (AIMD) Q4 2025 earnings summary

Executive summary

• Achieved 499% year-over-year revenue growth in 2025, driven by AI Nose commercialization.

• Transitioned AI Nose focus from healthcare to industrial markets, establishing partnerships for scale.

• Entering 2026 with operational momentum and early deployments in semiconductor environments.

Financial highlights

• Total revenue for 2025 was $124,157, up 499% year-over-year; gross margin improved to 82.9% from a gross loss in 2024.

• Operating expenses, excluding share-based compensation, depreciation, and amortization, decreased 9% year-over-year; reported operating expenses increased 2%.

• Net loss for 2025 was $14,771,012, compared to $14,863,161 in 2024.

• Cash and cash equivalents at year-end 2025 were $417,353, down from $3,892,919 at year-end 2024.

• Total assets decreased to $20.9 million at December 31, 2025, from $28.8 million a year earlier.

Outlook and guidance

• Early-stage AI Nose deployments in semiconductor environments are underway in 2026, with ~200 systems targeted for 1Q 2026 validation.

• A three-year, $2.1 million deployment for ~1,400 systems in semiconductor packaging/testing is targeted for Q2 2026 completion, with potential to scale to 20,000 systems.

• Additional liquidity secured post-year-end via NT$90 million (approx. $2.82 million USD) financing to support ongoing operations and scaling.